Rediscovering the Orbit of Percutaneous Coronary Intervention After ORBITA.

The publication of the Objective Randomised Blinded Investigation with Optimal Medical Therapy of Angioplasty in Stable Angina (ORBITA) trial generated an immense amount of discussion, debate, and controversy.1 The editorialists posed in their title whether the ORBITA trial is the "Last nail in the coffin for PCI in stable angina?"2 The ensuing press coverage has been extensive, though mostly one-sided and largely following the negative tone set by the editorial. The exchange on social media has been at times vitriolic, both pro and con - the number of Tweets of the article (1716 as of February 25, 2018) now exceeds the number of patients enrolled by over seven-fold. Thus, ORBITA has disrupted the orbit of PCI! [ABSTRACT FROM AUTHOR]